PDCD11 silencing restores SKP2‐mediated ubiquitination‐proteasomal degradation of C‐MYC to suppress tumor growth and metastasis, thus highlighting a potential PDCD11‐targeted regimen to combat p53‐mutant malignancies by indirectly destroying “undruggable” C‐MYC. Here, PDCD11 is linked to neoplasm.